All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

etripamil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, verapamil derivatives	5792	1593673-23-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: etripamil cardamyst MSP-2017

Etripamil is an L-type calcium influx inhibitor (slow channel blocker or calcium ion antagonist). Etripamil exerts its pharmacologic effect by modulating the influx of ionic calcium across the cell membrane of the AV nodal cells as well as arterial smooth muscles and contractile myocardial cells. By interrupting reentry at the AV node, etripamil can restore sinus rhythm in patients with PSVT. Molecular weight: 452.60 Formula: C27H36N2O4 CLOGP: 4.86 LIPINSKI: 1 HAC: 6 HDO: 0 TPSA: 71.79 ALOGS: ROTB: 13 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
Dec. 12, 2025	FDA	Milestone Pharmaceuticals

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08DA03	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS Phenylalkylamine derivatives
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators

Related Drugs by ATC class:

C08DA Phenylalkylamine derivatives 2 drugs

gallopamilverapamil

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Paroxysmal supraventricular tachycardia	indication	67198005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
70MG	CARDAMYST	MILESTONE PHARMS USA	N218571	Dec. 12, 2025	RX	SPRAY	NASAL	10010522	June 19, 2028	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
70MG	CARDAMYST	MILESTONE PHARMS USA	N218571	Dec. 12, 2025	RX	SPRAY	NASAL	9463179	June 19, 2028	TREATMENT OF A CARDIAC ARRHYTHMIA
70MG	CARDAMYST	MILESTONE PHARMS USA	N218571	Dec. 12, 2025	RX	SPRAY	NASAL	10117848	April 13, 2036	TREATMENT OF A CARDIAC ARRHYTHMIA
70MG	CARDAMYST	MILESTONE PHARMS USA	N218571	Dec. 12, 2025	RX	SPRAY	NASAL	12257224	July 15, 2042	TREATMENT OF A CARDIAC ARRHYTHMIA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
70MG	CARDAMYST	MILESTONE PHARMS USA	N218571	Dec. 12, 2025	RX	SPRAY	NASAL	Dec. 12, 2030	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel	Q13936	CAC1C_HUMAN	BLOCKER	IC50	7.64		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
1593673-23-4	SECONDARY_CAS_RN
CHEMBL3707312	ChEMBL_ID
C000656646	MESH_SUPPLEMENTAL_RECORD_UI
DB12605	DRUGBANK_ID
4044475	VANDF
C4519151	UMLSCUI
10134	INN_ID
D10932	KEGG_DRUG
91824132	PUBCHEM_CID
399954	MMSL
44585	MMSL
d10348	MMSL
020310	NDDF
14304	IUPHAR_LIGAND_ID
S82A18Y42P	UNII
2730302	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cardamyst	HUMAN PRESCRIPTION DRUG LABEL	1	83468-070	SPRAY	70 mg	NASAL	NDA	28 sections